Professor Dr Wan Nurazreena Wan Hassan is a Senior Consultant Orthodontist at the Faculty of Dentistry, Universiti Malaya, whose scholarship bridges digital dentistry with outcomes science in orthodontics. She is a subject-matter expert in Orthodontic-related quality of life (psychometrics as applied to malocclusion), treatment need, and patient-centred outcomes. Her leadership in dental education is demonstrated through pivotal roles as Deputy Dean (Postgraduate), previously Deputy Dean (Undergraduate) and Head of Department (cum Year 5 Leader, BDS), and Coordinator of the Orthodontic Postgraduate Programme, where she has led curriculum design and quality, assessment reform, and learner outcomes. Clinically, she integrates UK training (Cardiff, Wales) with a mini-preceptorship in Korea and a mini-residency in Japan to manage complex orthodontic cases, including cleft and craniofacial care, orthognathic surgery pathways, and obstructive sleep apnoea, translating multi-country best practices into Malaysian settings. Nationally, she serves on the Dental Specialist Evaluation Committee (DSEC) of the Malaysian Dental Council and contributes to evidence-based care, including the Clinical Practice Guidelines on Obstructive Sleep Apnoea (OSA) and guidelines in orthodontics. Internationally, she is an Examiner (MOrth Part II and MFDS) for the Royal College of Surgeons of England and Royal College of Physicians and Surgeons of Glasgow. Her academic influence includes an H-index of 11 (Web of Science) and 320 citations. She continues to expand her research through supervision of more than 23 postgraduates (9 completed PhD/Clinical Doctorate/Clinical Masters; 5 completed masters; 6 ongoing PhD/Clinical Doctorate; 3 ongoing masters) and 15 undergraduate elective project pairs, leads competitive grants, and publishes widely on patient-centred outcomes, digital workflows, quality measurement, and dental education.

Associate Professor Dr. Chen Yeng is an expert in cancer biomarker discovery, biosensor development, and natural therapeutics, with a multidisciplinary approach that bridges nanotechnology, molecular biology, and biomedicine. Her expertise is particularly evident in her work on innovative diagnostic technologies and personalized therapeutic solutions, targeting both cancer and infectious diseases.  Her research interests span several cutting-edge areas. One of her primary focuses is the identification and characterization of cancer biomarkers, particularly through novel approaches targeting at immunogenic host proteins. This line of research explores how immunogenic proteins’ interventions might modulate cancer risk, representing an innovative intersection of microbiology, proteomics, and oncology.  Dr. Chen is also deeply engaged in developing advanced diagnostic tools, including nanobiosensors with enhanced sensitivity and specificity. These devices, designed to detect critical biomarkers such as those associated with tuberculosis, blood clotting disorders, and oral cancer, are transformative for early disease detection. Her work in biosensors, utilizing materials like gold nanoparticles and zinc oxide nanolayers, has set new standards in diagnostic accuracy and reliability.  Another cornerstone of her research is the study of natural plant extracts for therapeutic applications, particularly in cancer treatment. She investigates the biochemical and pharmacological properties of these extracts, focusing on their mechanisms of action, such as inducing apoptosis, causing cell cycle arrest, and promoting mitochondrial dysfunction in cancer cells. Her exploration of natural products' roles in modulating microRNAs further highlights her innovative approach to cancer research.  Dr. Chen’s expertise also extends to the antioxidant, hepatoprotective, and genoprotective properties of herbal compounds, offering potential preventive and therapeutic solutions for chronic diseases. These studies underline her commitment to sustainable and natural approaches in healthcare.  Her contributions to genomics and proteomics, particularly in large-scale screening for biological markers, further demonstrate her role as a leader in translating complex biological data into meaningful clinical applications. By combining her deep understanding of molecular biology with a focus on real-world impact, Dr. Chen has established herself as a pioneer in her field.  Dr. Chen’s academic influence is demonstrated by her impressive h-index of 28 (ResearchID) and 39 (Scopus), with over 4,500 citations to her name. Her extensive publication record spans high-impact journals, contributing significantly to advancements in dentistry, oncology, and biomedical engineering. She is recognized as a top scientist in Malaysia, ranking among the leading figures in dentistry according to the AD Scientific Index. As a respected peer reviewer for prestigious journals, including Coordination Chemistry Reviews, Periodontal 2000, Biosensors and Bioelectronics, and Cancer Letters, Dr. Chen plays a critical role in maintaining the quality of research within her fields of expertise. Her contributions extend to academic leadership, where she had supervised and graduated over 20 postgraduate students, including 11 PhD candidates, nurturing the next generation of scientific leaders. Her leadership in dental education accreditation has further solidified her impact on academic excellence. She has played pivotal roles in the reaccreditation of dental programs at the University of Malaya and other institutions, ensuring that these programs meet global standards. Through her commitment to interdisciplinary collaboration, Dr. Chen has partnered with industry leaders to translate research findings into practical healthcare solutions, such as rapid diagnostic tools and personalized treatments. These collaborations exemplify her ability to bridge scientific discovery with real-world applications. In summary, Dr. Chen’s expertise and research interests reflect a holistic approach to biomedical science, integrating cutting-edge technologies with sustainable practices. Her work not only pushes the boundaries of knowledge in cancer research and diagnostics but also has the potential to transform patient care and public health globally.

Dr. Leong research focus on investigating the mechanism of action of potent compounds toward developing new anticancer and antidiabetes drugs. His research adopts an in vitro approach using cell-based and enzymatic assays to identify the various cellular pathways modulated by a potent compound. The research outcome is to understand the mechanism of action of the compound, a prerequisite requirement in developing a new drug entity. In addition, he employs metabolomics to evaluate biomarkers in explaining the treatment outcomes or disease progression. International collaboration has geared his research towards cancer stem cells and utilizing zebrafish as an animal model for cancer. It is believed that cancer stem cells is a subset of cells in tumour that drives chemoresistance and relapse in cancer patients. Therefore, strategies to develop new chemotherapy against the subset of cells is of great interest to tackle the problem.